Deep Neural Network Stratification for Use Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck)

Recruiting

• Conditions: Endometriosis

• Registration Number: NCT05245695
• Lead Sponsor: Aspira Women's Health

Brief Summary

The goal of this observational study is to determine the clinical validity of a deep neural network algorithm that utilizes protein biomarker detection of Endometriosis - "EndoCheck" - as an "aid in diagnosis" for endometriosis and to show validity as a diagnostic test

Detailed Description

The objective is to confirm the clinical performance (sensitivity and specificity) of EndoCheck when compared to laparoscopic surgical assessment as an "aid in diagnosis" for endometriosis in subjects who present with chronic pelvic pain.

The primary endpoint of the study is to optimize the test to achieve the success criteria of at least 94% and 79% sensitivity and specificity, respectively. Secondary endpoints include examining the performance of the test in patients stratified by pain severity and other clinical factors.

Study Timeline

• Study First Submitted: 2022-02-01
• Study First Submitted QC: 2022-02-08
• Study First Posted: 2022-02-18
• Study Start: 2022-07-12
• Status Verified: 2025-01
• Last Update Submitted: 2025-01-24
• Last Update Posted: 2025-01-28
• Primary Completion: 2025-07-31
• Study Completion: 2025-07-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 1200

Inclusion Criteria

• Participant is willing and able to provide written informed consent.
• Participant is a female aged 14 to 50 years old at time of consent.
• Participant is scheduled to undergo laparotomy or laparoscopy for symptomology consistent with possible endometriosis

Exclusion Criteria

• Participant is a female in a pre-menarchal state.
• Participant is pregnant.
• Participant has an active malignancy.
• Participant is known to have tested positive for human immunodeficiency virus or hepatitis A, B, or C.
• Participant has an active pelvic infection or other infections contraindicated for surgery.
• Participant has participated (±3 months of study enrollment) in a clinical trial where an investigational drug/ device/ procedure was or is planned to be administered.
• Participant has any general health or behavioral condition that, in the opinion of the investigator, should exclude the participant from participation.
• Participant is under 14 years old or over 50 years old

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Sensitivity and Specificity	24 months	The primary endpoint of the study is to optimize the test to achieve the success criteria of at least 94% and 79% sensitivity and specificity, respectively

Secondary Outcome Measures

Name	Time	Method
Performance	24 months	Examining the performance of the test in patients stratified by pain severity and other clinical factors.

Trial Locations

Locations (11)

Cindy Basinski, MD; 🇺🇸 Newburg, Indiana, United States

New Horizons Clinical Trials; 🇺🇸 Chandler, Arizona, United States

Arizona Gynecology Consultants; 🇺🇸 Mesa, Arizona, United States

Reproductive Associates of Delaware (RAD); 🇺🇸 Newark, Delaware, United States

Midtown OBGYN North; 🇺🇸 Columbus, Georgia, United States

Advanced Women's Care Center; 🇺🇸 Stockbridge, Georgia, United States

Johns Hopkins School of Medicine; 🇺🇸 Baltimore, Maryland, United States

Nezhat Surgery for Gynecology/Oncology; 🇺🇸 Valley Stream, New York, United States

Axia Women's Health; 🇺🇸 Cincinnati, Ohio, United States

May Grant; 🇺🇸 Lancaster, Pennsylvania, United States

Womens Health Services of Central Virginia; 🇺🇸 Lynchburg, Virginia, United States